Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Diabetology & Metabolic Syndrome
Published in: Diabetology & Metabolic Syndrome 1/2014

Open Access 01-12-2014 | Research

Oxidized low density lipoprotein and total antioxidant capacity in type-2 diabetic and impaired glucose tolerance Saudi men

Authors: Essam Eldin Mohamed Nour Eldin, Abdullah Almarzouki, Adel Mohamed Assiri, Osman Mohammed Elsheikh, Badreldin Elsonni Abdalla Mohamed, Abdullatif Taha Babakr

Published in: Diabetology & Metabolic Syndrome | Issue 1/2014

Login to get access

Abstract

Background

Oxidative modification of low density lipoproteins (LDL) convert these native particles into pathogenic, immunogenic and atherogenic particles. Factors enhance LDL oxidation are poorly understood, especially in conditions of hyperglycemia. The present study was conducted to investigate which metabolic conditions are associated with the promotion of LDL oxidation in different glycemic situations.

Methods

Adult male participants (274) were selected from patients admitted to the outpatient department of Diabetes Center in Al-Noor Specialized Hospital in Makkah and other citizens and residents in the city. The studied group was classified into three sub-groups: Group-I: control group of non-diabetic normal subjects, Group-II: subjects with impaired glucose tolerance (IGT) and Group-III: cases of type-2 diabetes mellitus (DM). Measurement of fasting blood glucose, 2 hour post-prandial blood glucose, glycosylated hemoglobin (HbA1c), triglycerides, serum cholesterol, HDL-cholesterol, LDL-cholesterol, ox-LDL, Total Antoxidant capacity (TAC) and Malondialdehyde (MDA) were performed. The obtained results were statistically analyzed.

Results

Oxidation of native LDL increase nearly two folds in Type-2 DM group compared to controls. There is also significant increase in Ox-LDL of IGT group compared to controls. The correlation between Ox-LDL concentration and HbA1c in the whole population of the study confirms the increased Ox-LDL in subjects with hyperglycemia. A negative correlation exists between the concentration of Ox-LDL and total antioxidant capacity (TAC) in each studied group and in the whole population of the study as well. A positive correlation also exists between Ox-LDL concentrations and LDL values, more clear in controls and Type-2 DM, while this correlation was not significant in IGT group. The ratio of LDL oxidation as expressed by ox-LDL/LDL was increased in IGT group compared to control. More significant increase was observed in type-2 DM group.

Conclusion

We concluded that the concentration of Ox-LDL increased in subjects with type-2 DM and IGT compared to controls. Moreover, oxidation of native LDL was associated with low levels of TAC and positively correlated with LDL levels, total cholesterol, HbA1c, body mass index (BMI) and increased age.
Appendix
Available only for authorised users
Literature
1.
Zuliani G, Morieri ML, Volpato S, Vigna GB, Tch CB, Maggio M, Cherubini A, Bandinelli S, Guralnik JM, Ferrucci L: Determinants and clinical significance of plasma oxidized LDLs in older individuals. A 9 years follow-up study. Atherosclerosis. 2013, 226: 201-207. 10.1016/j.atherosclerosis.2012.10.028.PubMedCentralCrossRefPubMed
2.
Lopes-Virella MF, Carter RE, Baker NL, Lachin J, Virella G, the DCCT/EDIC Research Group: Sunday, 26 August 2012. High levels of oxidized LDL in circulating immune complexes are associated with increased odds of developing abnormal albuminuria in Type 1 diabetes. Eur Heart J. 2012, 33: 19-338. 10.1093/eurheartj/ehs281.CrossRef
3.
Perrin-Cocon L, Diaz O, Andre P, Lotteau V: Modified lipoproteins provide lipids that modulate dendritic cell immune function. Biochimie. 2013, 95: 103-108. 10.1016/j.biochi.2012.08.006.CrossRefPubMed
4.
Kaplan M, Aviram M, Hayek T: Oxidative stress and macrophage foam cell formation during diabetes mellitus-induced atherogenesis: role of insulin therapy. Pharmacol Ther. 2012, 136: 175-185. 10.1016/j.pharmthera.2012.08.002.CrossRefPubMed
5.
El-Bassiouni EA, Helmy MH, El-Zoghby SM, El-Nabi Kamel MA, Hosny RM: Relationship between level of circulating modified LDL and the extent of coronary artery disease in type 2 diabetic patients. Br J Biomed Sci. 2007, 64: 109-116.PubMed
6.
Yang H, Mohamed AS, Zhou SH: Oxidized low density lipoprotein, stem cells, and atherosclerosis. Lipids Health Dis. 2012, 11: 85-10.1186/1476-511X-11-85.PubMedCentralCrossRefPubMed
7.
Ishigaki Y, Oka Y, Katagiri H: Circulating oxidized LDL: a biomarker and a pathogenic factor. Curr Opin Lipidol. 2009, 20: 363-369. 10.1097/MOL.0b013e32832fa58d.CrossRefPubMed
8.
Tsimikas S, Miller YI: Oxidative modification of lipoproteins: mechanisms, role in inflammation and potential clinical applications in cardiovascular disease. Curr Pharm Des. 2011, 17: 27-37. 10.2174/138161211795049831.CrossRefPubMed
9.
Wang Y, Chun OK, Song WO: Plasma and dietary antioxidant status as cardiovascular disease risk factors: a review of human studies. Nutrients. 2013, 5: 2969-3004. 10.3390/nu5082969.PubMedCentralCrossRefPubMed
10.
Rajkovic N, Zamaklar M, Lalic K, Lalic NM, Popovic L, Draskovic-Radojkovic D, Singh S, Stosic L, Jotic A, Lukic L, Milicic T: OP3: Oxidized LDL as residual lipid risk marker in type 2 diabetes. Diabetes Metab. 2012, 38 (Supplement 5): S98-S99.CrossRef
11.
Kosola J, Vaara JP, Ahotupa M, Kyrolainen H, Santtila M, Oksala N, Atalay M, Vasankari T: Elevated concentration of oxidized LDL together with poor cardiorespiratory and abdominal muscle fitness predicts metabolic syndrome in young men. Metabolism. 2013, 62: 992-999. 10.1016/j.metabol.2013.01.013.CrossRefPubMed
12.
Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, Kitzmiller J, Knowler WC, Lebovitz H, Lernmark A, Nathan D, Palmer J, Rizza R, Saudek C, Shaw J, Steffes M, Stern M, Tuomilehto J, Zimmet P: Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003, 26: 3160-3167.CrossRefPubMed
13.
Holvoet P, Macy E, Landeloos M, Jones D, Jenny NS, Van de Werf F, Tracy RP: Analytical performance and diagnostic accuracy of immunometric assays for the measurement of circulating oxidized LDL. Clin Chem. 2006, 52: 760-764. 10.1373/clinchem.2005.064337.CrossRefPubMed
14.
Miller NJ, Rice-Evans CA: Factors influencing the antioxidant activity determined by the ABTS. + radical cation assay. Free Radic Res. 1997, 26: 195-199. 10.3109/10715769709097799.CrossRefPubMed
15.
Dawn-Linsley M, Ekinci FJ, Ortiz D, Rogers E, Shea TB: Monitoring thiobarbituric acid-reactive substances (TBARs) as an assay for oxidative damage in neuronal cultures and central nervous system. J Neurosci Methods. 2005, 141: 219-222. 10.1016/j.jneumeth.2004.06.010.CrossRefPubMed
16.
Matsumoto H, Uchino M, Kato M: Evaluation of haemoglobin A1c measurement by an enzymatic method using an automated analyser that has an on-board haemolysis system. Ann Clin Biochem. 2013, 50: 443-449. 10.1177/0004563213476859.CrossRefPubMed
17.
Matsuda M, Tamura R, Kanno K, Segawa T, Kinoshita H, Nishimoto O, Nishiyama H, Kawamoto T: Impact of dyslipidemic components of metabolic syndrome, adiponectin levels, and anti-diabetes medications on malondialdehyde-modified low-density lipoprotein levels in statin-treated diabetes patients with coronary artery disease. Diabetology Metab Syndrome. 2013, 5: 77-10.1186/1758-5996-5-77.CrossRef
18.
Gomez M, Molina L, Bruguera J, Sala J, Masia R, Munoz-Aguayo D, Tomas M, Heredia S, Blanchart G, Gaixas S, Vila J, Fito M: Oxidized low-density lipoprotein antibodies in myocardial infarction patients without classical risk factors. J Cardiovasc Med (Hagerstown). 2014, 15: 417-422. 10.2459/JCM.0b013e3283638d79.CrossRef
19.
Li S, Kievit P, Robertson AK, Kolumam G, Li X, von Wachenfeldt K, Valfridsson C, Bullens S, Messaoudi I, Bader L, Cowan KJ, Kamath A, van Bruggen N, Bunting S, Frendeus B, Grove KL: Targeting oxidized LDL improves insulin sensitivity and immune cell function in obese Rhesus macaques. Mol Metab. 2013, 2: 256-269. 10.1016/j.molmet.2013.06.001.PubMedCentralCrossRefPubMed
20.
21.
Kopprasch S, Pietzsch J, Kuhlisch E, Fuecker K, Temelkova-Kurktschiev T, Hanefeld M, Kuhne H, Julius U, Graessler J: In vivo evidence for increased oxidation of circulating LDL in impaired glucose tolerance. Diabetes. 2002, 51: 3102-3106. 10.2337/diabetes.51.10.3102.CrossRefPubMed
22.
Di Renzo L, Carraro A, Valente R, Iacopino L, Colica C, De Lorenzo A: Intake of red wine in different meals modulates oxidized LDL level, oxidative and inflammatory gene expression in healthy people: a randomized crossover trial. Oxid Med Cell Longev. 2014, 2014: 681318-PubMedCentralPubMed
23.
Castilla P, Echarri R, Davalos A, Cerrato F, Ortega H, Teruel JL, Lucas MF, Gomez-Coronado D, Ortuno J, Lasuncion MA: Concentrated red grape juice exerts antioxidant, hypolipidemic, and antiinflammatory effects in both hemodialysis patients and healthy subjects. Am J Clin Nutr. 2006, 84: 252-262.PubMed
24.
Hirano-Ohmori R, Takahashi R, Momiyama Y, Taniguchi H, Yonemura A, Tamai S, Umegaki K, Nakamura H, Kondo K, Ohsuzu F: Green tea consumption and serum malondialdehyde-modified LDL concentrations in healthy subjects. J Am Coll Nutr. 2005, 24: 342-346. 10.1080/07315724.2005.10719483.CrossRefPubMed
25.
Baba S, Natsume M, Yasuda A, Nakamura Y, Tamura T, Osakabe N, Kanegae M, Kondo K: Plasma LDL and HDL cholesterol and oxidized LDL concentrations are altered in normo- and hypercholesterolemic humans after intake of different levels of cocoa powder. J Nutr. 2007, 137: 1436-1441.PubMed
26.
Basu A, Betts NM, Ortiz J, Simmons B, Wu M, Lyons TJ: Low-energy cranberry juice decreases lipid oxidation and increases plasma antioxidant capacity in women with metabolic syndrome. Nutr Res. 2011, 31: 190-196. 10.1016/j.nutres.2011.02.003.PubMedCentralCrossRefPubMed
27.
Winklhofer-Roob BM, Rock E, Ribalta J, Shmerling DH, Roob JM: Effects of vitamin E and carotenoid status on oxidative stress in health and disease. Evidence obtained from human intervention studies. Mol Aspects Med. 2003, 24: 391-402. 10.1016/S0098-2997(03)00035-9.CrossRefPubMed
28.
Folchetti LD, Monfort-Pires M, de Barros CR, Martini LA, Ferreira SR: Association of fruits and vegetables consumption and related-vitamins with inflammatory and oxidative stress markers in prediabetic individuals. Diabetology Metab Syndrome. 2014, 6: 22-10.1186/1758-5996-6-22.CrossRef
29.
American Diabetes A: Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014, 37 (Suppl 1): S81-S90.CrossRef
30.
Al-Nozha MM, Al-Maatouq MA, Al-Mazrou YY, Al-Harthi SS, Arafah MR, Khalil MZ, Khan NB, Al-Khadra A, Al-Marzouki K, Nouh MS, Abdullah M, Attas O, Al-Shahid MS, Al-Mobeireek A: Diabetes mellitus in Saudi Arabia. Saudi Med J. 2004, 25: 1603-1610.PubMed
31.
Whiting DR, Guariguata L, Weil C, Shaw J: IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011, 94: 311-321. 10.1016/j.diabres.2011.10.029.CrossRefPubMed
32.
Al-Daghri NM, Al-Attas OS, Alokail MS, Alkharfy KM, Yousef M, Sabico SL, Chrousos GP: Diabetes mellitus type 2 and other chronic non-communicable diseases in the central region, Saudi Arabia (Riyadh cohort 2): a decade of an epidemic. BMC Med. 2011, 9: 76-10.1186/1741-7015-9-76.PubMedCentralCrossRefPubMed
33.
Schwenke DC, D'Agostino RB, Goff DC, Karter AJ, Rewers MJ, Wagenknecht LE: Differences in LDL oxidizability by glycemic status: the insulin resistance atherosclerosis study. Diabetes Care. 2003, 26: 1449-1455. 10.2337/diacare.26.5.1449.CrossRefPubMed
34.
35.
Caparevic Z, Kostic N: [The influence of age and the beginning of menopause on the lipid status, LDL oxidation, and CRP in healthy women]. Srp Arh Celok Lek. 2007, 135: 280-285. 10.2298/SARH0706280C.CrossRefPubMed
36.
Li Y, Saito M, Tobimatsu S, Oshida H, Hori Y, Fuchigami H, Munakata H, Nakajima K: Prediabetes and impaired lung function in asymptomatic adults. Diabetes Res Clin Pract. 2013, 100: e51-e54. 10.1016/j.diabres.2013.01.021.CrossRefPubMed
37.
Luca AC, Iordache C: Obesity–a risk factor for cardiovascular diseases. Rev Med Chir Soc Med Nat Iasi. 2013, 117: 65-71.PubMed
38.
Ma RC, Lee HM, Lam VK, Tam CH, Ho JS, Zhao HL, Guan J, Kong AP, Lau E, Zhang G, Luk A, Wang Y, Tsui SK, Chan TF, Hu C, Jia WP, Park KS, Lee HK, Furuta H, Nanjo K, Tai ES, Ng DP, Tang NL, Woo J, Leung PC, Xue H, Wong J, Leung PS, Lau TC, Tong PC: Familial young-onset diabetes, pre-diabetes and cardiovascular disease are associated with genetic variants of DACH1 in Chinese. PLoS One. 2014, 9: e84770-10.1371/journal.pone.0084770.PubMedCentralCrossRefPubMed
39.
Ng DS: Diabetic dyslipidemia: from evolving pathophysiological insight to emerging therapeutic targets. Can J Diabetes. 2013, 37: 319-326. 10.1016/j.jcjd.2013.07.062.CrossRefPubMed
40.
Diwadkar VA, Anderson JW, Bridges SR, Gowri MS, Oelgten PR: Postprandial low-density lipoproteins in type 2 diabetes are oxidized more extensively than fasting diabetes and control samples. Proc Soc Exp Biol Med. 1999, 222: 178-184. 10.1046/j.1525-1373.1999.d01-129.x.CrossRefPubMed
41.
Magge SN, Prasad D, Koren D, Gallagher PR, Mohler ER, Stettler N, Levitt Katz LE, Rader DJ: Prediabetic obese adolescents have a more atherogenic lipoprotein profile compared with normoglycemic obese peers. J Pediatr. 2012, 161: 881-886. 10.1016/j.jpeds.2012.04.006.PubMedCentralCrossRefPubMed
42.
Khan HA, Sobki SH, Khan SA: Association between glycaemic control and serum lipids profile in type 2 diabetic patients: HbA1c predicts dyslipidaemia. Clin Exp Med. 2007, 7: 24-29. 10.1007/s10238-007-0121-3.CrossRefPubMed
43.
Habib SS: Body mass index and body fat percentage in assessment of obesity prevalence in saudi adults. Biomed Environ Sci. 2013, 26: 94-99.PubMed
Metadata
Title
Oxidized low density lipoprotein and total antioxidant capacity in type-2 diabetic and impaired glucose tolerance Saudi men
Authors
Essam Eldin Mohamed Nour Eldin
Abdullah Almarzouki
Adel Mohamed Assiri
Osman Mohammed Elsheikh
Badreldin Elsonni Abdalla Mohamed
Abdullatif Taha Babakr
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Diabetology & Metabolic Syndrome / Issue 1/2014
Electronic ISSN: 1758-5996
DOI
https://doi.org/10.1186/1758-5996-6-94

Other articles of this Issue 1/2014

Diabetology & Metabolic Syndrome 1/2014 Go to the issue

Research

Visceral adiposity index score indicated the severity of coronary heart disease in Chinese adults

Research

Neuroendocrine and metabolic components of dopamine agonist amelioration of metabolic syndrome in SHR rats

Research

Effect of repaglinide versus glimepiride on daily blood glucose variability and changes in blood inflammatory and oxidative stress markers

Retraction Note

Retraction Note: Low birth weight: causes and consequences

Research

Liraglutide counteracts obesity and glucose intolerance in a mouse model of glucocorticoid-induced metabolic syndrome

Research

Association and interaction analysis of PPARGC1A and serum uric acid on type 2 diabetes mellitus in Chinese Han population

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits